CHD

Business profile & competitive position

Church & Dwight Co., Inc. operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. Its business is built on a portfolio of familiar consumer brands: ARM & HAMMER, OXICLEAN, BATISTE, WATERPIK, THERABREATH, HERO, TOUCHLAND, TROJAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, and ZICAM. The company reports through three operating segments: Consumer Domestic, Consumer International, and a Specialty Products Division that covers animal nutrition, specialty chemicals, and commercial/professional cleaners.

The competitive posture shows up most clearly in profitability. The trailing net margin is 12.0% and return on equity is 17.8%. Those figures are consistent with a consumer-staples business that earns pricing power from repeated household purchases and shelf placement. A more granular sign of concentration sits in the so-called “power brands,” which contributed roughly 70% of consolidated net sales and profits in 2025. That concentration can amplify brand equity, but it also means the company's aggregate growth is heavily tied to the performance of a handful of labels.

Another structural feature is customer concentration. Walmart accounted for about 23% of consolidated net sales in 2025, and no other customer exceeded 10% over the previous three years. Within Consumer Domestic, household products represented approximately 54% of segment net sales and personal care represented approximately 46% in 2025. Distribution leverage and repeat purchases help explain the margin profile; at the same time, a single customer approaching a quarter of revenue is a vulnerability if pricing negotiations or shelf resets turn difficult.

Financial posture

At a $23.4 billion market cap, Church & Dwight trades at a trailing P/E of 31.6. That valuation is materially above what one would expect from a slow-growth, purely defensive name, so the market is clearly pricing in above-average earnings quality, brand durability, or both. The 12.0% net margin and 17.8% ROE support that premium relative to weaker consumer staples, though the multiple also leaves little room for execution missteps.

The stock's beta of 0.47 confirms its defensive character: it historically moves less than half as much as the broad market during risk-on or risk-off swings. The current snapshot at the time of the data shows the stock at $98.55, with an RSI of 43.9 and the 50-day EMA at $99.35. Price is essentially hugging the 50-day moving average and RSI is near neutral, which suggests neither extreme accumulation nor distribution in recent sessions. For an income-oriented holder, the 247wallst.com headline noting Church & Dwight among consumer staples that keep raising dividends is a reminder that the financial posture also includes a long track record of returning cash to shareholders.

Strategic priorities & outlook

According to the company's most recent 10-K, Church & Dwight is actively repositioning its portfolio toward faster-growing value and premium product lines. That repositioning follows deliberate exits: the company has moved on from Flawless, Spinbrush, Waterpik showerhead, and the VMS (vitamins, minerals, supplements) brands. The exit strategy is intended to leave a cleaner growth footprint, though the lost sales from those brands will need to be offset by the remaining portfolio.

One of the nearest-term priorities is integrating the Touchland hand-sanitizer acquisition and realizing its intended contribution to sales and earnings. Touchland is positioned as a premium personal-care addition, which may help the mix shift toward higher-margin products. The company also intends to expand the seven power brands globally, citing significant global expansion potential. International therefore remains a central growth lever.

Operationally, the filing emphasizes supply-chain resilience. Management states the goal of maintaining qualified dual sources for roughly 70% of direct materials spend. That dual-sourcing target is a direct response to the supply-chain volatility of recent years and should reduce the risk of a single-supplier shutdown disrupting production.

Macro & geopolitical exposure

As a Household & Personal Products company, Church & Dwight faces macro exposures that are typical of the sector but still material. Input costs are a primary concern: packaging resins, chemicals, pulp-based materials, and freight all feed into household and personal-care goods. Any sustained increase in those inputs can pressure the 12.0% net margin unless pricing actions or cost efficiencies offset it.

Currency translation matters because Consumer International is a reporting segment. A stronger U.S. dollar would shrink the dollar value of overseas revenue and earnings, while a weaker dollar does the reverse. The company is also exposed to regulatory scrutiny common in consumer staples, including product-safety standards, labeling requirements, and environmental rules for packaging and chemicals. Trade policy can matter as well: tariffs on imported raw materials or finished goods, or retaliatory tariffs in export markets, could alter cost structures or geographic growth plans. The dual-sourcing policy mentioned in the 10-K is one way the company is trying to mitigate those supply-chain risks.

Recent developments

The most recent news flow around CHD has been constructive. On September 1, 2026, Beacon Pointe Advisors LLC disclosed a $742,000 investment in Church & Dwight, according to defenseworld.net. A day earlier, on August 31, 2026, Corient Private Wealth LP also reported a new investment in the company via the same outlet. Meanwhile, 247wallst.com included Church & Dwight in a list of “4 Battle-Tested Consumer Staples Stocks That Keep Raising Their Dividends,” published August 31, 2026. The same day, invezz.com highlighted Bank of America's picks, noting that BofA named 3 stocks with meaningful upside in September—with CHD apparently among them.

None of these items are fundamental earnings events, but they do indicate that institutional allocators and sell-side strategists are viewing the stock as a defensive place to hide in a choppy market. That aligns with the low beta, though the stock's actual reaction to its own earnings reports in 2026 has been more nuanced.

Earnings behavior & post-earnings drift

Church & Dwight's earnings history over the last eight reported quarters shows a 6/8 beat rate, or 75% (86% per the headline beat-rate convention), with an average earnings surprise of 5.2%. Across those quarters, the average 5-day price move after the report has been 1.32% to the upside. On the surface, that looks like a stock that rewards beats, but the underlying pattern is more complicated.

The most notable takeaway is that beats have not reliably produced follow-through in the same direction as the surprise. In the last four reported quarters: July 31, 2026 was a miss—actual EPS of $0.89 versus an estimate of $0.896, a -0.7% surprise—yet the stock moved up 1.21% the next day and 4.48% over the following five days. May 1, 2026 was a beat: $0.95 vs. $0.931, a 2.0% surprise, but the stock fell 3.26% the next day and 2.69% over the next five days. January 30, 2026 delivered a 2.9% beat ($0.86 vs. $0.836) and produced a clean bidirectional reaction: up 1.13% the next day and 4.45% over five days. October 31, 2025 was the largest beat of the group at 10.1% ($0.81 vs. $0.736), but the stock dropped 1.61% the next day and 0.95% over five days.

That disconnect matters for anyone trading CHD around earnings. The unofficial consensus may be for a beat, and the historical beat rate is high, but the market's real expectation could already be embedded in a premium valuation. When forward guidance, margin commentary, or segment mix disappoints, even a headline beat can be sold. The next earnings report is scheduled for October 30, 2026, before the market open, with a consensus EPS estimate of $0.90.

For a deeper dive into how institutional analysts are currently weighting these same factors—the premium valuation, the power-brand growth profile, and the mixed post-earnings drift pattern—readers should consult the full institutional verdict on CHD rather than relying on any single data snapshot.